research Topical Application of Aprepitant Inhibits Erlotinib-induced Facial Dermatitis/Hair Loss
In this study, researchers found that applying topical aprepitant, which blocks substance P receptors, significantly reduced facial dermatitis and hair loss in rats experiencing erlotinib-induced skin side effects, highlighting the neurogenic inflammation's role and the protective effect of ROS inhibition.